Lynparza approved in China for 1L BRCAm ovarian
(WorldNews Sweden)

Lynparza approved in China for 1L BRCAm ovarian 05 December 2019 07:00 GMT Lynparza approved in China as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer AstraZeneca and MSD`s Lynparza reduced the risk of disease progression or death by 70% in BRCAm advanced ovarian cancer after response to 1st- line platinum-based chemotherapy Only PARP inhibitor approved in this setting in China AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from China`s National Medical Products Administration (NMPA) for Lynparza (olaparib) as a 1st-line maintenance...